Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00051155 · ClinicalTrials.gov registry record · Phase 3

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

A Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Alcon Research.

Completed
Registry status
Phase 3
Development phase
1
Study location

NCT00051155: Completed Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Alcon Research.

NCT00051155 is a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Alcon Research. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00051155, a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 3
Development phase
1
Study location

Study Summary

To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.

Interventions

  • DRUG Travoprost (0.004%)
  • DRUG Latanoprost (0.005%)/Timolol (0.5%)

Study Locations (1)

Texas

  • Europe - Fort Worth

Trial Details

FieldValue
Start Date 2001-01
Est. Completion 2004-07
Phase Phase 3
Alcon Research

275 total trials

What the finished NCT00051155 record still lists

NCT00051155 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Travoprost (0.004%) is the first listed.

NCT00051155 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00051155 about?

NCT00051155 is a clinical study titled "A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)". To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT00051155?

This trial is currently completed. It is a Phase 3 study. The study started on 2001-01. Estimated completion is 2004-07.

What conditions does trial NCT00051155 study?

This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.

What interventions are being tested in trial NCT00051155?

The interventions under investigation include: Travoprost (0.004%) (DRUG), Latanoprost (0.005%)/Timolol (0.5%) (DRUG).

Who is sponsoring clinical trial NCT00051155?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00051155 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00051155, the US trial registry maintained by the National Library of Medicine. NCT00051155 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.